Peptides in the Spotlight: From GLP-1 to the Next Wave

A quick guide to:

Peptides have moved well beyond the laboratory. Today, they appear in conversations about weight loss, metabolic health, muscle recovery, injury, skin aging, and longevity. However, the evidence behind these compounds varies enormously.

This is the second article in the peptide-focused chapter within our Hype vs. Reality series. After exploring what peptides are, we now shift the focus to some of the names attracting the most attention and, importantly, how much science actually sits behind that attention.

At one end of the spectrum are peptide-based medicines studied in thousands of people. At the other are compounds whose reputations have largely been built on animal experiments, small studies, and online enthusiasm [1].

GLP-1, short for glucagon-like peptide-1, is a hormone your gut naturally releases after eating. It helps control blood sugar by prompting the body to release insulin when needed, reducing signals that raise blood sugar, slowing digestion, and helping feel full [2].

Natural GLP-1 survives in circulation for only a short time. Researchers therefore developed longer-lasting molecules that activate the same receptor, known as GLP-1 receptor agonists.

This distinction is worth making: medications such as semaglutide are not simply injections of the body's natural GLP-1. They are engineered peptide-based drugs designed to reproduce aspects of GLP-1 signalling while remaining active much longer [2].

Originally developed for type 2 diabetes, GLP-1 receptor agonists attracted much wider attention when large clinical trials demonstrated substantial weight loss. In the STEP 1 trial, adults with overweight or obesity receiving semaglutide lost approximately 15% of their body weight on average over 68 weeks, compared with about 2% with placebo [3].

Then came tirzepatide, another peptide drug often grouped into the “GLP-1” conversation. More precisely, tirzepatide activates receptors for both GLP-1 and GIP, another gut hormone involved in regulating blood sugar and metabolism. In the SURMOUNT-1 trial, average weight loss reached approximately 21% at the highest tested dose after 72 weeks [4].

These are not effects extrapolated from cells or mice. They come from large randomized human trials, which is an important reason GLP-1-based therapies occupy a very different scientific category from many other peptides currently circulating online.

GLP-1 medicines can be commonly misunderstood as simply drugs that “make people eat less.” Appetite reduction is important, but biology is more complex. GLP-1 signaling affects glucose regulation, insulin secretion, gastrointestinal function, and neural pathways involved in food intake [2].

The clinical effects also extend beyond the number on a scale.

In the SELECT trial, semaglutide reduced the risk of major cardiovascular events by 20% compared with placebo in more than 17,000 adults with overweight or obesity and established cardiovascular disease but without diabetes [5]. That finding is highly relevant to healthspan. It does not, however, mean that semaglutide has been demonstrated to slow biological aging or extend lifespan in healthy people.

This distinction matters because reducing a major risk factor for age-related disease in people with existing health risks is not the same as proving that a treatment slows aging itself.

Nor do GLP-1 medicines permanently “reset” metabolism. In an extension of the STEP 1 trial, participants regained approximately two-thirds of their previous weight loss during the year after semaglutide was stopped [6]. Obesity is a chronic biological condition, and for many patients these drugs may function as long-term therapies rather than temporary interventions.

Their risks and limitations, including gastrointestinal side effects, loss of muscle mass, appropriate patient selection, and questions around long-term use, deserve their own discussion, which we will address more thoroughly later in this series.

Outside established medicines, a different group of peptides has become increasingly visible in fitness, recovery, and longevity circles.

BPC-157 is commonly promoted for tendon healing, muscle recovery, gastrointestinal repair, and inflammation. In animal studies, it has been associated with faster tissue repair, including increased collagen formation, new blood vessel growth, and improved strength and organization of healing tendons, ligaments, and muscle [7]. These findings are promising, but they come overwhelmingly from preclinical models rather than robust human trials. A 2026 review found that available clinical evidence involved fewer than 30 people across several uncontrolled pilot studies, with no validated dosing regimen and no completed Phase II clinical trial [7].

That is not to say that BPC-157 is ineffective. It simply means the confident claims commonly made about it are far ahead of the evidence required to establish that it works safely in humans, and therefore warrants a level of caution.

A similar problem surrounds TB-500, which is promoted for tissue repair and recovery. Preclinical studies have generated biological interest, but rigorous human evidence supporting many of the uses advertised online remains sparse [8].

Another popular category aims to influence the growth hormone–IGF-1 axis, such as CJC-1295 and ipamorelin, which, in simple terms, are designed to encourage the body to release more growth hormone.

There is evidence that they can affect this pathway. Small human studies have shown that CJC-1295 can increase circulating growth hormone and IGF-1 levels, for example [9]. But, showing that a compound raises a hormone is not the same as demonstrating that it improves muscle mass, recovery, performance, or healthy aging.

This is a recurring theme in peptide discussions: showing that a peptide changes a hormone level or biological process in the body is not the same as proving that it improves health, recovery, performance, or longevity. Recent reviews of performance-related peptides conclude that human efficacy and long-term safety data remain limited for many of these compounds [8].

Not all popular peptides are injected.

GHK-Cu, often called a copper peptide, appears widely in skincare and “anti-aging” products. It has been studied for effects related to collagen production, wound healing, and tissue regeneration.

Here again, promising biology has sometimes been translated into stronger marketing claims than the clinical literature supports. Laboratory evidence is substantial, but reviews have highlighted the surprising lack of robust clinical studies demonstrating how well topical GHK-Cu penetrates human skin and produces meaningful anti-aging effects [10].

A peptide appearing in a cosmetic formulation does not automatically mean enough of it reaches the relevant tissue to reproduce effects seen in laboratory experiments.

GLP-1 drugs, BPC-157, CJC-1295, and GHK-Cu may all be described as “peptides,” but scientifically they should not be placed in the same bucket.

Some peptide medicines have been tested in large randomized trials, with known doses, manufacturing standards, measurable benefits, and increasingly well-characterized risks. Others have convincing biological mechanisms but very limited clinical evidence. Others remain primarily experimental.

For the Longevity Science Foundation, this distinction is central to separating hype from reality. Longevity science should be open to promising new interventions, but enthusiasm should rise in proportion to the evidence.

Peptides may ultimately provide important tools for metabolic disease, regeneration, and healthy aging. GLP-1 therapies already demonstrate how powerful peptide-based medicine can become when biological insight is translated through rigorous clinical research.

The challenge is not to assume that every peptide will follow the same path but to determine which ones actually do.